Multiplexed Ovarian Cancer Microfluidic Tissue Microarray

Information

  • Research Project
  • 8648455
  • ApplicationId
    8648455
  • Core Project Number
    R43CA177146
  • Full Project Number
    1R43CA177146-01A1
  • Serial Number
    177146
  • FOA Number
    PA-13-088
  • Sub Project Id
  • Project Start Date
    7/15/2014 - 10 years ago
  • Project End Date
    6/30/2016 - 8 years ago
  • Program Officer Name
    RAHBAR, AMIR M.
  • Budget Start Date
    7/15/2014 - 10 years ago
  • Budget End Date
    6/30/2016 - 8 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    7/15/2014 - 10 years ago

Multiplexed Ovarian Cancer Microfluidic Tissue Microarray

Project Summary We propose an instrument system for automated, multiplexed cell- and tissue-based experiments (i.e. tissue microarrays) called the Microfluidic Flow Cell Array (MFCA). The MFCA consists of a microfluidic flow cell array integrated with an inverted fluorescent microscope, allowing the observation of 48 flow chambers simultaneously or an individual chamber at higher magnification. The proposed instrument will be used to novel cell- and tissue-based assays in a highly parallel manner that are otherwise difficult to perform. Our goal is to build a platform for producing a tissue microarray that maintains many of the characteristics found in cells in vivo and allows for the investigation of cell-surface, cell-cell, and especially tumor-stroma interactions, cell toxicity studies, and tissue toxicity studies in a multiplexed fashion. As a Phase I application, this proposal's focus is ovarian cancer tissue slice toxicity testing to determine the optimal chemotherapeutic agents for a specific patient (i.e. personalized treatment based on the tissue reaction); however, multiple applications can be envisioned beyond ovarian cancer including: combinatorial cell stimulation, toxicity, or therapeutic assays, stem cell screening and differentiation control studies, multiplexed primary cell assays, biomaterials screening, shear stress and cell adhesion studies, and combinatorial immunohistochemistry. This platform approach and simple integration with a microscope will allow for adoption and adaptability for researchers worldwide. The following hypotheses and specific aims have been identified to prove the feasibility of integrating the microfluidic flow cell array technology with an inverted fluorescent microscope for cell and tissue based assays. Specific Aim 1. Translate end point assays for existing tissue culture approaches including the MTT Assay and digital pathology to the MFCA. Specific Aim 2. Engineer the MFCA printhead to minimize impact of the printhead docking onto the tissue culture slice. Specific Aim 3. Optimize drug delivery of different therapeutic agents in the MFCA channels using to the mouse ovarian tissue slice and compare to existing tissue culture approaches.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    225000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:225000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WASATCH MICROFLUIDICS
  • Organization Department
  • Organization DUNS
    171205177
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    841234436
  • Organization District
    UNITED STATES